ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

Lessons from Caring for the Underinsured & Uninsured

Samantha C. Shapiro, MD  |  February 17, 2022

As the first rheumatologist at a federally qualified health center in Austin, Texas, Samantha Shapiro, MD, learned several practical tips for the care of uninsured and underinsured patients with rheumatic diseases.

Filed under:Practice Support Tagged with:Dr. Veena Patelfederally qualified health centerhealthcare accessMedical Access Programpatient careuninsured Americans

Improving Lupus Drug Regimen Adherence Among Minorities

Michael Putman, MD  |  February 10, 2022

Rheumatologists can do better at helping systemic lupus erythematosus patients from racial and ethnic minority groups adhere to their lupus medication regimens, according to a paper published in Arthritis Care & Research. Researchers from Duke University examined medication adherence barriers from the perspectives of healthcare providers and patients. Their findings suggest more attention should be…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:adherenceDisparities

Andrew Brookes / Image Source on Offset

Clinical Insights into Axial Spondyloarthritis: Rheumatology Drugs at a Glance, Part 5

Mary Choy, PharmD, BCGP, FASHP  |  February 10, 2022

Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options; others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

Filed under:Axial SpondyloarthritisBiologics/DMARDsConditionsDrug Updates Tagged with:Ankylosing SpondylitisAS Resource Center

Clinical Insights into Gout Management: Q&A with Dr. Tuhina Neogi

Mary Choy, PharmD, BCGP, FASHP  |  February 9, 2022

Gout affects more than 9.2 million adults in the U.S. and is the most common form of inflammatory arthritis. This condition and its complications are painful and potentially disabling with varying risk factors. It is characterized by symptoms that are usually sudden, with intense episodes of painful swelling in one or more joints, most often…

Filed under:ACR ConvergenceClinical Criteria/GuidelinesConditionsDrug UpdatesGout and Crystalline ArthritisMeeting Reports Tagged with:Dr. Tuhina NeogiGoutGout Resource Center

Highlights from ACR Convergence’s Late-Breaking Abstracts

Samantha C. Shapiro, MD  |  February 2, 2022

COVID-19 vaccination, treatments for rheumatic disease and more—the Late-Breaking Abstracts session of ACR Convergence 2021 highlighted six studies with implications for rheumatology.

Filed under:ACR ConvergenceMeeting ReportsResearch Rheum Tagged with:ACR Convergence 2021COVID-19emapalumabgiant cell arteritis (GCA)Researchrituximabsecukinumabvaccines

The 2021 ACR Awards of Distinction & Distinguished Fellows

Patrice Fusillo  |  December 16, 2021

During ACR Convergence 2021 in early November, the ACR honored a group of individuals who have made significant contributions to rheumatology research, education and patient care, announcing the recipients of the ACR’s 2021 Awards of Distinction, as well as the group of Distinguished Fellows. recognized for their contributions. Three pediatric rheumatologists and one pediatric fellow…

Filed under:AwardsProfessional Topics Tagged with:Dr. Alfredo AguirreDr. Alisa A. MuellerDr. Amanda E. NelsonDr. Anne R. BassDr. Brian M. FeldmanDr. Bryce A. BinstadtDr. Ida Dzifa DeyDr. Jacqueline MadisonDr. Jose U. ScherDr. Madelaine “Mattie” FeldmanDr. Mariana J. KaplanDr. Maximilian F. KonigDr. Michael H. WeismanDr. Naomi J. PatelDr. Philip SeoDr. Richard K. VeheDr. Rochelle L. CastilloDr. Roseanne F. ZhaoDr. Seoyoung C. KimDr. Sokratis ApostolidisDr. Stanley B. Cohen

Alpha Tauri 3D Graphics / shutterstock.com

Rheumatic Complications from Immune Checkpoint Inhibitors

Nilasha Ghosh, MD, MS, & Anne R. Bass, MD  |  December 16, 2021

Immune checkpoint inhibitors (ICIs), such as anti-programmed cell-death 1/programmed death-ligand 1 (anti-PD-1/PD-L1) or anti-CTL-associated protein (anti-CTLA-4), have dramatically changed the treatment of advanced cancers over the past decade. ICIs block T cell inhibition, thus increasing the anti-tumor immune response. ICIs are used not only for metastatic cancer, but also as adjuvant treatment for some stage…

Filed under:Conditions Tagged with:immune checkpoint inhibitor (ICI)immune-related adverse events

Research on SLE, pJIA & More Highlighted in 2nd ACR Convergence 2021 Plenary Session

Samantha C. Shapiro, MD  |  December 9, 2021

Experts shined a spotlight on select abstracts of the latest rheumatology research, addressing such topics as racial disparities in the management of children with SLE, vitamin D or fish oil supplementation to prevent autoimmune disease & more.

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric ConditionsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2021ACR Convergence 2021 – SLECOVID-19MIS-CPediatricpJIApolyarticular juvenile idiopathic arthritis

Cardiovascular Risks & Insights from ACR Convergence 2021

Thomas R. Collins  |  December 9, 2021

Experts share insights into how LDL & HDL levels are affected by inflammation & the treatment of rheumatic disease, addressing how targeting these levels may improve cardiovascular outcomes for patients.

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2021

New Findings on COVID-19 Vaccination, Race & More Shared in 1st Plenary Session

Thomas R. Collins  |  December 9, 2021

Researchers shared findings on the immune response to COVID-19 vaccination in immunocompromised patients, insights into cognitive impairment in SLE & more.

Filed under:ACR ConvergenceAxial SpondyloarthritisConditionsMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2021ACR Convergence 2021 – RACOVID-19Disparities

  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 107
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences